Stay updated on Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page.

Latest updates to the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page
- Check3 days agoChange DetectedThe investigators section was updated to include Hiroaki Akamatsu and adjust institution references. New help/navigation items were added (How to Read a Study Record, Common Questions, How to Join a Study), the Intervention/Treatment label formatting was updated, and the revision tag changed from v3.5.5 to v3.6.0.SummaryDifference2%

- Check10 days agoChange DetectedThe page now shows Revision: v3.5.5, indicating a new site revision. This replaces the previous Revision: v3.5.4 and reflects a minor platform update.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedRevision: v3.5.4 was added to the page, replacing the previous v3.5.3. This indicates a site software/version update for the ClinicalTrials.gov page, with no evident changes to the study's details or eligibility criteria.SummaryDifference0.1%

- Check52 days agoChange DetectedThe study page’s footer revision/version indicator was updated from v3.5.2 to v3.5.3, reflecting a site/version update rather than a change to the trial information itself.SummaryDifference0.1%

- Check60 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check88 days agoChange DetectedRevision: v3.5.0 was added and Revision: v3.4.3 was removed.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page.